Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sara Crystal

Neurology New York, NY Medical Doctor

NPI 1992996110 CMS profile 1046604

30 E 76Th St, 2Nd Floor, New York, NY 10021

Open in the dashboard

General payments

$55,859

332 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sara Crystal of New York, NY is reported in the CMS Open Payments database as having received $55,859 across 332 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,877 23
2024 General $1,674 13
2023 General $5,584 27
2022 General $9,758 68
2021 General $18,769 105
2020 General $16,274 62
2019 General $1,922 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sara Crystal
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Sara Crystal were reported at $1,877. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Sara Crystal Neurology median Middle half National median
2019 $1,922 $474 $118–$2,177 $163
2020 $16,274 $367 $82–$2,309 $114
2021 $18,769 $438 $104–$2,547 $132
2022 $9,758 $442 $103–$2,388 $149
2023 $5,584 $464 $119–$2,312 $160
2024 $1,674 $468 $119–$2,323 $164
2025 $1,877 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $22,916 126 payments
  2. Allergan Inc. $18,051 61 payments
  3. Biohaven Pharmaceuticals, Inc. $7,398 45 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $3,368 28 payments
  5. Pfizer Inc. $1,726 13 payments
  6. Promius Pharma LLC $1,059 3 payments
  7. Sentynl Therapeutics, Inc. $517 2 payments
  8. Teva Pharmaceuticals USA, Inc. $232 23 payments
  9. Novartis Pharmaceuticals Corporation $160 8 payments
  10. Amgen Inc. $140 7 payments
  11. Other $292 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $48,160 37 payments
  2. Food and Beverage $4,507 285 payments
  3. Consulting Fee $3,042 5 payments
  4. Travel and Lodging $128 2 payments
  5. Education $22 3 payments
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $22,586 85 payments
  2. UBRELVY Neuroscience $15,662 44 payments
  3. NURTEC ODT Primary Care $10,765 73 payments
  4. QULIPTA $7,303 44 payments
  5. NURTEC ODT Pain $1,726 13 payments
  6. AIMOVIG $299 15 payments
  7. BOTOX Botox Therapeutic $206 10 payments
  8. BOTOX Hyperhydrosis $193 13 payments
  9. Ajovy $182 20 payments
  10. PAXLOVID $146 9 payments
  11. Other $788 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

81

Median for Psychiatry & Neurology: 100

Drug cost

$79,722

Median for Psychiatry & Neurology: $2,986

Branded share of claims

86.4%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Botox Onabotulinumtoxina Brand 70 $79,544
Topiramate Generic 11 $178

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $1,517
$1,517 — —
BOTOX
  • AbbVie, Inc. $66
$66 70 —
NURTEC ODT
  • PFIZER INC. $28
$28 — —
ZAVZPRET
  • PFIZER INC. $28
$28 — —
UBRELVY
  • AbbVie, Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record